

FINANCIAL TEAR SHEET

Corporate Profile

Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer immunotherapy products. We utilize the body's own machinery – the T-cell – to target and destroy cancer cells by increasing the affinity of naturally occurring T-cell receptors (TCRs). We have developed a proprietary T-cell receptor platform that enables us to identify cancer targets, find and genetically engineer T-cell receptors, or TCRs, and produce TCR therapeutic candidates called SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cells that recognize these targets on cancer cells. We engineer a patient's own T-cells to express our SPEAR TCRs to target and potentially destroy tumors.

Our wholly-owned pipeline includes SPEAR T-cell therapies targeting ADP-A2M10 (MAGE-A10), ADP-A2M4 (MAGE-A4), and ADP-A2AFP (AFP), which are being investigated in clinical studies across multiple solid tumor indications. We continue to build a pipeline of further proprietary TCR therapeutic candidates, second generation treatment options, as well as allogeneic (off-the-shelf) solutions.

We believe our approach will lead to SPEAR T-cells with the potential to significantly impact cancer treatment and the clinical outcomes of cancer patients.

Primary IR Contact

Investor Contact

Email:


IR@adaptimmune.com

Stock Performance

ADAP (AMERICAN DEPOSITARY SHARES)

Exchange	NASDAQ GS (US Dollar)
Price	\$4.86
Change (%)	▼ 0.18 (3.57%)
Volume	434,215
52 Week Low	\$3.60
Market Cap	\$3,049,274,312
Rolling EPS	-0.93
PE Ratio	0
Shares Outstanding	627,422,698

Data as of 01/18/19 4:00 p.m. ET



Recent Headlines & Events

01/07/19

[Dose Escalation in Liver Cancer Study with ADP-A2AFP \(AFP\) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 \(MAGE-A10\) Lung Cancer Study after Favorable Safety Reviews](#)

12/12/18

[Adaptimmune Announces that Gwen Binder will leave in January 2019](#)

11/06/18

[Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update](#)

There are currently no events scheduled.

SEC Filings

FILING DATE

FORM

Corporate Governance

[James Noble](#)

Chief Executive Officer

01/16/19	<u>4</u>	<u>Bent Jakobsen, PhD</u>	Scientific Founder
01/16/19	<u>4</u>	<u>Helen Tayton-Martin, PhD, MBA</u>	Chief Business Officer
01/16/19	<u>4</u>	<u>Rafael Amado, MD</u>	President Research and Development
01/16/19	<u>4</u>	<u>Adrian Rawcliffe</u>	Chief Financial Officer
		<u>Gwendolyn Binder, PhD</u>	Chief Technology Officer
		<u>William (Bill) Bertrand</u>	Chief Operating Officer

Data provided by Nasdaq. Minimum 15 minutes delayed.